ASH2021注目テーマ「Late-Breaking Abstracts Session #3」

siRNA治療薬fitusiranが重症血友病A
およびB患者の年間出血率を有意に低減
：ATLAS-A/B 試験 Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia A or B without Inhibitors (ATLAS-A/B) (#LBA-3)

Alok Srivastava（Christian Medical College, Vellore, India）